-transparent.png){kind=logo}
Cisplatin-containing regimens have shown activity in both small and non-small cell lung cancer. We therefore conducted a randomized Phase II trial of the new platinum congeners iproplatin and carboplatin in bronchogenic carcinoma. The overall response rate in chemotherapy-naive non-small cell patients with iproplatin was 3/48 (6%; 95% confidence interval 2-18%) and with carboplatin 6/50 (12%; 95% confidence interval 5-25%). The response rates in previously treated small cell patients were 0/16 and 1/18, respectively. Overall, neither agent has pronounced activity in bronchogenic carcinoma.
Related Publications
B S Kramer, and
R Birch, and
A Greco, and
K Prestridge, and
P DeSimone, and
G Omura
September 1987,
Cancer treatment reports,
B S Kramer, and
R Birch, and
A Greco, and
K Prestridge, and
P DeSimone, and
G Omura
January 1991,
Cancer chemotherapy and pharmacology,
B S Kramer, and
R Birch, and
A Greco, and
K Prestridge, and
P DeSimone, and
G Omura
December 1993,
American journal of clinical oncology,
B S Kramer, and
R Birch, and
A Greco, and
K Prestridge, and
P DeSimone, and
G Omura
January 1991,
European journal of cancer (Oxford, England : 1990),
B S Kramer, and
R Birch, and
A Greco, and
K Prestridge, and
P DeSimone, and
G Omura
August 1989,
American journal of clinical oncology,
B S Kramer, and
R Birch, and
A Greco, and
K Prestridge, and
P DeSimone, and
G Omura
April 1989,
American journal of clinical oncology,
B S Kramer, and
R Birch, and
A Greco, and
K Prestridge, and
P DeSimone, and
G Omura
January 1987,
Cancer chemotherapy and pharmacology,
B S Kramer, and
R Birch, and
A Greco, and
K Prestridge, and
P DeSimone, and
G Omura
January 1988,
Cancer chemotherapy and pharmacology,
B S Kramer, and
R Birch, and
A Greco, and
K Prestridge, and
P DeSimone, and
G Omura
January 1994,
Investigational new drugs,
B S Kramer, and
R Birch, and
A Greco, and
K Prestridge, and
P DeSimone, and
G Omura
July 1992,
Investigational new drugs,
